Marta Castiglia Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology University of Palermo Biography Publications Institution JoVE Articles Marta Castiglia has not added a biography. If you are Marta Castiglia and would like to personalize this page please email our Author Liaison for assistance. Publications Can the MicroRNA Expression Profile Help to Identify Novel Targets for Zoledronic Acid in Breast Cancer? Oncotarget. Apr, 2016 | Pubmed ID: 27081088 Dietary Restriction: Could It Be Considered As Speed Bump on Tumor Progression Road? Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. Jun, 2016 | Pubmed ID: 27043958 Exosomes Isolation and Characterization in Serum is Feasible in Non-small Cell Lung Cancer Patients: Critical Analysis of Evidence and Potential Role in Clinical Practice Oncotarget. Feb, 2016 | Pubmed ID: 26919248 A Headlight on Liquid Biopsies: a Challenging Tool for Breast Cancer Management Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine. Apr, 2016 | Pubmed ID: 26790442 Stabilizing Versus Destabilizing the Microtubules: a Double-edge Sword for an Effective Cancer Treatment Option? Analytical Cellular Pathology (Amsterdam). 2015 | Pubmed ID: 26484003 Prognostic and Predictive Biomarkers for Targeted Therapy in NSCLC: for Whom the Bell Tolls? Expert Opinion on Biological Therapy. 2015 | Pubmed ID: 26360115 New Findings on Primary and Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer: Do All Roads Lead to RAS? Oncotarget. Sep, 2015 | Pubmed ID: 26318427 Improvement in Lung Cancer Outcomes with Targeted Therapies: an Update for Family Physicians Journal of the American Board of Family Medicine : JABFM. Jan-Feb, 2015 | Pubmed ID: 25567833 Cancer and the Microbiome: Potential Applications As New Tumor Biomarker Expert Review of Anticancer Therapy. Mar, 2015 | Pubmed ID: 25495037 ALK and Crizotinib: After the Honeymoon…what Else? Resistance Mechanisms and New Therapies to Overcome It Translational Lung Cancer Research. Aug, 2014 | Pubmed ID: 25806308 Liquid Biopsies in Lung Cancer: the New Ambrosia of Researchers Biochimica Et Biophysica Acta. Dec, 2014 | Pubmed ID: 25444714 Immunotherapy: is a Minor God Yet in the Pantheon of Treatments for Lung Cancer? Expert Review of Anticancer Therapy. Oct, 2014 | Pubmed ID: 25148289 Are Erlotinib and Gefitinib Interchangeable, Opposite or Complementary for Non-small Cell Lung Cancer Treatment? Biological, Pharmacological and Clinical Aspects Critical Reviews in Oncology/hematology. Feb, 2014 | Pubmed ID: 24041630 Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines BioMed Research International. 2013 | Pubmed ID: 24171172 HIF-1 is Involved in the Negative Regulation of AURKA Expression in Breast Cancer Cell Lines Under Hypoxic Conditions Breast Cancer Research and Treatment. Aug, 2013 | Pubmed ID: 23925655 qPCR sayesinde küçük hücre dışı akciğer kanseri (KHDAK) Hasta Plazma içinde Exosomal miRNA Analizi: Bir Uygulanabilir Sıvı Biyopsi Aracı Marco Giallombardo*1,2, Jorge Chacártegui Borrás*2,3, Marta Castiglia4, Nele Van Der Steen3, Inge Mertens5,6, Patrick Pauwels7,3, Marc Peeters8,3, Christian Rolfo2,3 1Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo, 2Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA), 3Center for Oncological Research (CORE), Antwerp University, 4Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 5Flemish Institute for Technological Research (VITO), 6CORE, Campus Groenenborger, Antwerp University, 7Molecular Pathology, Pathology Department, Antwerp University Hospital (UZA), 8Oncology Department, Antwerp University Hospital (UZA) Medicine
qPCR sayesinde küçük hücre dışı akciğer kanseri (KHDAK) Hasta Plazma içinde Exosomal miRNA Analizi: Bir Uygulanabilir Sıvı Biyopsi Aracı Marco Giallombardo*1,2, Jorge Chacártegui Borrás*2,3, Marta Castiglia4, Nele Van Der Steen3, Inge Mertens5,6, Patrick Pauwels7,3, Marc Peeters8,3, Christian Rolfo2,3 1Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo, 2Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA), 3Center for Oncological Research (CORE), Antwerp University, 4Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 5Flemish Institute for Technological Research (VITO), 6CORE, Campus Groenenborger, Antwerp University, 7Molecular Pathology, Pathology Department, Antwerp University Hospital (UZA), 8Oncology Department, Antwerp University Hospital (UZA) Medicine
